These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29408314)

  • 1. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.
    Kabashima A; Hirsova P; Bronk SF; Hernandez MC; Truty MJ; Ilyas SI; Kaufmann SH; Gores GJ
    J Hepatol; 2018 Jun; 68(6):1228-1238. PubMed ID: 29408314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
    Raggi C; Taddei ML; Sacco E; Navari N; Correnti M; Piombanti B; Pastore M; Campani C; Pranzini E; Iorio J; Lori G; Lottini T; Peano C; Cibella J; Lewinska M; Andersen JB; di Tommaso L; Viganò L; Di Maira G; Madiai S; Ramazzotti M; Orlandi I; Arcangeli A; Chiarugi P; Marra F
    J Hepatol; 2021 Jun; 74(6):1373-1385. PubMed ID: 33484774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
    Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
    J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
    Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
    Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting FGFR inhibition in cholangiocarcinoma.
    Goyal L; Kongpetch S; Crolley VE; Bridgewater J
    Cancer Treat Rev; 2021 Apr; 95():102170. PubMed ID: 33735689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.
    Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
    Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
    Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
    Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines.
    Dokduang H; Jamnongkarn W; Promraksa B; Suksawat M; Padthaisong S; Thanee M; Phetcharaburanin J; Namwat N; Sangkhamanon S; Titapun A; Khuntikeo N; Klanrit P; Loilome W
    Drug Des Devel Ther; 2020; 14():2319-2334. PubMed ID: 32606601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actinidia arguta (Hardy Kiwi) Root Extract Exerts Anti-cancer Effects via Mcl-1-Mediated Apoptosis in Cholangiocarcinoma.
    Zhao X; Wen F; Wang W; Lu Z; Guo Q
    Nutr Cancer; 2019; 71(2):246-256. PubMed ID: 30633583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma.
    Raggi C; Fiaccadori K; Pastore M; Correnti M; Piombanti B; Forti E; Navari N; Abbadessa G; Hall T; Destro A; Di Tommaso L; Roncalli M; Meng F; Glaser S; Rovida E; Peraldo-Neia C; Olaizola P; Banales JM; Gerussi A; Elvevi A; Droz Dit Busset M; Bhoori S; Mazzaferro V; Alpini G; Marra F; Invernizzi P
    Am J Pathol; 2019 Oct; 189(10):2090-2101. PubMed ID: 31351075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
    Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
    Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.
    Lampis A; Carotenuto P; Vlachogiannis G; Cascione L; Hedayat S; Burke R; Clarke P; Bosma E; Simbolo M; Scarpa A; Yu S; Cole R; Smyth E; Mateos JF; Begum R; Hezelova B; Eltahir Z; Wotherspoon A; Fotiadis N; Bali MA; Nepal C; Khan K; Stubbs M; Hahne JC; Gasparini P; Guzzardo V; Croce CM; Eccles S; Fassan M; Cunningham D; Andersen JB; Workman P; Valeri N; Braconi C
    Gastroenterology; 2018 Mar; 154(4):1066-1079.e5. PubMed ID: 29113809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways and targeted therapy in cholangiocarcinoma.
    Dabney RS; Khalife M; Shahid K; Phan AT
    Clin Adv Hematol Oncol; 2019 Nov; 17(11):630-637. PubMed ID: 31851165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
    Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
    Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SRPK Inhibitors Reduce the Phosphorylation and Translocation of SR Protein Splicing Factors, thereby Correcting
    Changphasuk P; Inpad C; Horpaopan S; Khunchai S; Phimsen S; Surangkul D; Janvilisri T; Silsirivanit A; Kaewkong W
    Front Biosci (Schol Ed); 2024 Sep; 16(3):17. PubMed ID: 39344395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ponatinib inhibits growth of patient-derived xenograft of cholangiocarcinoma expressing FGFR2-CCDC6 fusion protein in nude mice].
    Wu T; Jiang X; Xu B; Wang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1448-1456. PubMed ID: 33118510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma.
    Lomphithak T; Choksi S; Mutirangura A; Tohtong R; Tencomnao T; Usubuchi H; Unno M; Sasano H; Jitkaew S
    Cell Commun Signal; 2020 Oct; 18(1):161. PubMed ID: 33036630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma.
    Zhen Y; Liu K; Shi L; Shah S; Xu Q; Ellis H; Balasooriya ER; Kreuzer J; Morris R; Baldwin AS; Juric D; Haas W; Bardeesy N
    Nat Commun; 2024 May; 15(1):3805. PubMed ID: 38714664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.